中恒集团：孙公司纳米炭铁混悬注射液临床试验获批

Core Viewpoint - The announcement highlights that Chongqing Laimei Pharmaceutical Co., Ltd., a subsidiary of Zhongheng Group, has received approval from the National Medical Products Administration for a clinical trial of its innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection" [1] Group 1 - The drug is intended for use in conjunction with standard radiotherapy for patients with solid tumors [1] - The approval allows for the initiation of clinical trials, indicating progress in the development of new cancer treatment options [1]